Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016106 | 1.00 | PIK3CD (0.49) | PIK3CDPDE4BGPR119IDO1TDO2 | |
| SCHEMBL1016279 | 0.85 | PIK3CD (0.50) | PIK3CDPDE4BGPR119IDO1TDO2 | |
| SCHEMBL1016278 | 0.85 | PIK3CD (0.50) | PIK3CDPDE4BGPR119IDO1TDO2 | |
| SCHEMBL22608970 | 0.83 | PDE4B (0.57) | PIK3CDPDE4BIDO1TDO2TP53 | |
| SCHEMBL9952336 | 0.82 | FASN (0.52) | PIK3CDPDE4BGPR119IDO1TDO2 | |
| SCHEMBL1012489 | 0.80 | ROCK2 (0.44) | ROCK2CCNCCDK8 | |
| SCHEMBL1012488 | 0.80 | ROCK2 (0.44) | ROCK2CCNCCDK8 | |
| SCHEMBL1016155 | 0.80 | PDE4B (0.53) | PDE4BGPR119SFRP1 | |
| SCHEMBL1016154 | 0.80 | PDE4B (0.53) | PDE4BGPR119SFRP1 | |
| SCHEMBL3328409 | 0.80 | PIK3CD (0.49) | PIK3CDPDE4BIDO1TDO2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2081890-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | PIK3CD 3580/4885PDE4B 1026/4885GPR119 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.